文献速递白血病造血干细胞移植与细胞治疗

奥英妥珠单抗治疗婴幼儿复发难治性急性淋巴细胞白血病:病例系列

Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
PubMed 文献 · Br J Haematol · 2021-02-02

首个疗程中位剂量1.74 mg/m2(分次给药),7例(47%)达完全缓解,另1例MRD阳性转为MRD阴性。6个月总生存率47%(95%CI 27-80%),2例移植后发生肝静脉闭塞病,提示需进一步评估InO在该亚组中的应用。

要点

  • InO在婴幼儿R/R ALL中47%达完全缓解,另1例MRD转阴。
  • 首个疗程中位剂量1.74 mg/m2(分次给药)。
  • 6个月总生存率47%,移植后2例发生肝静脉闭塞病。

核心结论

  • InO在婴幼儿复发/难治性ALL中显示一定疗效,值得进一步评估。

主要发现

  • 7例(47%)达完全缓解,另1例MRD阳性转为MRD阴性。
  • 6个月总生存率47%(95%CI 27-80%)。
  • 2例移植后发生肝静脉闭塞病。
  • 中位CD22+原始细胞百分比72%(范围40-100%,n=9)。

关键数值与推荐

  • 首个疗程中位剂量1.74 mg/m2(分次给药)。

临床怎么用

  • InO可作为婴幼儿复发/难治性ALL的桥接治疗选择,需警惕移植后肝静脉闭塞病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40-100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27-80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Brivio E, Chantrain CF, Gruber TA, et al. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series. Br J Haematol. 2021. PMID: 33529389. doi:10.1111/bjh.17333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。